# Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

> **NCT02920697** · PHASE1 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 65 (actual)

## Conditions studied

- Chronic Lymphocytic Leukaemia (CLL)
- B-Cell Non-Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)

## Interventions

- **DRUG:** S 55746

## Key facts

- **NCT ID:** NCT02920697
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-10-22
- **Final completion:** 2018-10-22
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920697, "Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02920697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*